Abstract
We sought to explore whether trimetazidine addition reduces QT dispersion early after acute myocardial infarction. Prospectively, we randomized 60 consecutive patients with first acute ST elevation myocardial infarction to receive either trimetazidine 20 mg tid (trimetazidine group 30 patients), or placebo (placebo group 30 patients). QT dispersion and corrected QT dispersion were measured on day 3 and day 7 of admission. Patients were followed during hospitalization for the occurrence of ventricular arrhythmias (sustained ventricular tachycardia or ventricular fibrillation). QT dispersion and corrected QT dispersion were significantly lower in trimetazidine group in both days, compared to control group: day 3, 58±5 msec versus 78±6 msec, and 69±11 msec versus 91±10 msec, respectively, p < 0.001 for both; day 7, 41±7 msec versus 60±8 msec, and 47±9 msec versus 69±6 msec, respectively, p < 0.0001 for both. This finding was consistent in all prespecified subgroups. During hospital stay, 3 patients (10%) of the placebo group developed sustained ventricular tachycardia and 2 (6.6%) died of ventricular fibrillation, but no one in the trimetazidine group had such arrhythmias. Conclusion: In patients with first acute myocardial infarction, the addition of trimetazidine significantly reduced both QT dispersion and corrected QT dispersion and reduced the occurrence of ventricular arrhythmias throughout hospitalization.
Keywords: Trimetazidine, QT dispersion, myocardial infarction
Current Drug Therapy
Title: Trimetazidine: Does it Actually Reduce QT Dispersion After First Acute Myocardial Infarction?
Volume: 4 Issue: 1
Author(s): Khaled El-Meniawy, Hanan Hafez, Hala Bamatraf and Wail Nammas
Affiliation:
Keywords: Trimetazidine, QT dispersion, myocardial infarction
Abstract: We sought to explore whether trimetazidine addition reduces QT dispersion early after acute myocardial infarction. Prospectively, we randomized 60 consecutive patients with first acute ST elevation myocardial infarction to receive either trimetazidine 20 mg tid (trimetazidine group 30 patients), or placebo (placebo group 30 patients). QT dispersion and corrected QT dispersion were measured on day 3 and day 7 of admission. Patients were followed during hospitalization for the occurrence of ventricular arrhythmias (sustained ventricular tachycardia or ventricular fibrillation). QT dispersion and corrected QT dispersion were significantly lower in trimetazidine group in both days, compared to control group: day 3, 58±5 msec versus 78±6 msec, and 69±11 msec versus 91±10 msec, respectively, p < 0.001 for both; day 7, 41±7 msec versus 60±8 msec, and 47±9 msec versus 69±6 msec, respectively, p < 0.0001 for both. This finding was consistent in all prespecified subgroups. During hospital stay, 3 patients (10%) of the placebo group developed sustained ventricular tachycardia and 2 (6.6%) died of ventricular fibrillation, but no one in the trimetazidine group had such arrhythmias. Conclusion: In patients with first acute myocardial infarction, the addition of trimetazidine significantly reduced both QT dispersion and corrected QT dispersion and reduced the occurrence of ventricular arrhythmias throughout hospitalization.
Export Options
About this article
Cite this article as:
El-Meniawy Khaled, Hafez Hanan, Bamatraf Hala and Nammas Wail, Trimetazidine: Does it Actually Reduce QT Dispersion After First Acute Myocardial Infarction?, Current Drug Therapy 2009; 4 (1) . https://dx.doi.org/10.2174/157488509787081822
DOI https://dx.doi.org/10.2174/157488509787081822 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytokine Gene Polymorphism in Heart Transplantation: A Review
Current Genomics Lone Atrial Fibrillation: Electrophysiology, Risk Factors, Catheter Ablation and Other Non-pharmacologic Treatments
Current Pharmaceutical Design A Comprehensive Review on Chrysin: Emphasis on Molecular Targets, Pharmacological Actions and Bio-pharmaceutical Aspects
Current Drug Targets Surgical Management of Heart Failure
Current Cardiology Reviews Effectiveness of Resveratrol Against Cardiovascular Disease
Mini-Reviews in Organic Chemistry Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Against Apoptosis
Current Pharmaceutical Design Heme Oxygenase-1 in Vascular Smooth Muscle Cells Counteracts Cardiovascular Damage Induced by Angiotensin II
Current Neurovascular Research Endothelial Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets
Current Medicinal Chemistry Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Recent Developments in Nanoparticle Based Targeted Delivery of Chemotherapeutics
Current Bioactive Compounds Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews Targeting ADAM12 in Human Disease: Head, Body or Tail?
Current Pharmaceutical Design Ryanodine Receptor - A Novel Therapeutic Target in Heart Disease
Recent Patents on Cardiovascular Drug Discovery Daunorubicin Metabolism in Leukemic Cells Isolated from Patients with Acute Myeloid Leukemia
Drug Metabolism Letters Bridging the Gap: The Potential Role of Corticosteroid Binding Globulin in Cardiac Steroid Facilitation
Current Drug Targets Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention
Current Drug Targets Chebulagic Acid Synergizes the Cytotoxicity of Doxorubicin in Human Hepatocellular Carcinoma Through COX-2 Dependant Modulation of MDR-1
Medicinal Chemistry Curcumin and its Multi-target Function Against Pain and Inflammation: An Update of Pre-clinical Data
Current Drug Targets Epigenetic Modulation of Myocardial Angiogenic Balance: An Emerging Therapeutic Perspective for Adult Failing Heart
Current Angiogenesis (Discontinued) Nutrigenomic Analysis of Diet-Gene Interactions on Functional Supplements for Weight Management
Current Genomics